Long-term pharmacotherapy for obesity and overweight

Cochrane Database of Systematic Reviews

Volumn 2010, Issue 1, 2003, Pages

  Padwal, Raj S ^a   Rucker, Diana ^b   Li, Stephanie K ^b   Curioni, Cintia ^c   Lau, David CW ^d  

^a UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^d UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANOREXIGENIC AGENT; ANTIOBESITY AGENT; CYCLOBUTANE DERIVATIVE; LACTONE; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

BODY WEIGHT; HUMAN; OBESITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); WEIGHT REDUCTION;

ANTI-OBESITY AGENTS; APPETITE DEPRESSANTS; BODY WEIGHT; CYCLOBUTANES; HUMANS; LACTONES; OBESITY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; WEIGHT LOSS;

EID: 85003220340     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD004094.pub2     Document Type: Review

References (131)

1. Apfelbaum M, Vague P, Ziegler O, Hanotin C, Thomas F, Leutenegger E. Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. American Journal of Medicine 1999;106:179-84.
2. Bakris G, Calhoun D, Egan B, Hellmann C, Dolker M, Kingma I. Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. Journal of Hypertension 2002;20:2257-67.
3. Berne C. A randomized study of orlistat in combination with a weight management programme in obese patients with type 2 diabetes treated with metformin. Diabet Med 2005;22:612-8.
4. Broom I, Wilding J, Stott P, Myers N. Randomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK Multimorbidity Study. International Journal of Clinical Practice 2002;56:494-9.
5. Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat. Journal of the American Medical Association 1999;281:235-42.
6. Derosa G, Mugellini A, Ciccarelli L, Fogari R. Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both on anthropometric measurements, blood pressure and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet. Clin Ther 2003;25:1107-1122.
7. Finer N, James WPT, Kopelman PG, Lean MEJ, Williams G. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. International Journal of Obesity and Related Metabolic Disorders 2000;24:306-13.
8. Hauner H, Meier M, Wendland G, et al. Weight reduction by sibutramine in obese subjects in primary care medicine: the SAT study. Exp Clin Endocrinol Diabetes 2004;112:201-7.
9. Hauptman J, Lucas C, Boldrin MN, Collins H, Segal K. Orlistat in the long-term treatment of obesity in primary care settings. Archives of Family Medicine 2000;9:160-7.
10. Hollander PA, Elbein SC, Hirsch IB, Kelley D, McGill J, Taylor T, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. Diabetes Care 1998;21:1288-94.
11. James WPT, Astrup A, Finer N, Hilsted J, Kopelman P, Rossner S, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. Lancet 2000;356:2119-25.
12. Kaukua JK, Pekkarinen TA, Rissanen AM. Health-related quality of life in a randomised placebo-controlled trial of sibutramine in obese patients with type II diabetes. Int J Obes Relat Metab Disord 2004;28:600-5.
13. Kelley DE, Bray GA, Pi-Sunyer FX, Klein S, Hill J, Miles J, Hollander P. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes. Diabetes Care 2002;25:1033-41.
14. Krempf M, Louvet JP, Allanic H, et al. Weight reduction and long-term maintenance after 18 months treatment with orlistat for obesity. Int J Obese Relat Met Disord 2003;27:591-7.
15. Lindgarde F. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: The Swedish Multimorbidity Study. Journal of Internal Medicine 2000;248:245-54.
16. Mathus-Vliegen EM for the Balance Study Group. Long-term maintenance of weight loss with sibutramine in a GP setting following a specialist guided very-low-calorie diet: a double-blind, placebo-controlled, parallel group study. European Journal of Clinical Nutrition 2005;59(Suppl 1):S31-39.
17. McMahon FG, Fujioka K, Singh BN, Mendel CM, Rowe E, Rolston K, et al. Efficacy and safety of sibutramine in obese white and African American patients with hypertension. Archives of Internal Medicine 2000;160:2185-91.
18. McMahon FG, Weinstein SP, Rowe E, Ernst KR, Johnson F, Fujioka K. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled by angiotensin converting enzyme inhibitors. Journal of Human Hypertension 2002;16:5-11.
19. McNulty SJ, Ur E, Williams G, et al. A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin. Diabetes Care 2003;26:125-131.
20. Miles JM, Leiter L, Hollander P, et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care 2002;25:1123-28.
21. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006;368:1660-72.
22. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005;365:1389-97.
23. Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005;353:2121-34.
24. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients. JAMA 2006;295:761-5.
25. Rossner S, Sjostrom L, Noack R, Meinders AE, Noseda G. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. Obesity Research 2000;8:49-61.
26. Sanchez-Reyes L, Fanghanel G, Yamamoto J, et al. Use of sibutramine in overweight adult Hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial. Clin Ther 2004;26:1427-35.
27. Sjostrom L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HPF, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998;352:167-73.
28. Smith IG, Goulder MA. Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. Journal of Family Practice 2001;50:505-12.
29. Swinburn BA, Carey D, Hills AP, et al. Effect of orlistat on cardiovascular disease risk in obese adults. Diab Obes Metab 2005;7:254-62.
30. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. Xenical in the prevention of diabetes in obese subjects (XENDOS) study. Diabetes Care 2004;1:155-61.
31. Derosa G, Mugellini A, Ciccarelli L, Rinaldi A, Fogari R. Effects of orlistat, simvastatin, and orlistat plus simvastatin in obese patients with hypercholesterolemia: a randomized, open-label trial. Current Therapeutic Research, Clinical and Experimental 2002;63:621-33.
32. Gaciong Z, Placha G. Efficacy and safety of sibutramine in 2225 subjects with cardiovascular risk factors: short-term, open-labl, observational study. Journal of Hum Hypertens 2005;19:737-43.
33. Gilbert S, Garrow JS. A prospective controlled trial of outpatients treatment for obesity. Human Nutrition. Clinical Nutrition 1983;37:21-9.
34. Hanefeld M, Sachse G. The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial. Diabetes, Obesity and Metabolism 2002;4:415-23.
35. Heymsfield SB, Segal KR, Hauptman J, Lucas CP, Boldrin MN, Rissanen A, et al. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Archives of Internal Medicine 2000;160:1321-26.
36. Hill JO, Hauptman J, Anderson JW, Fujioka K, O'Neil PM, Smith DK, et al. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study. American Journal of Clinical Nutrition 1999;69:1108-16.
37. Hsieh CJ, Wang PW, Liu RT, et al. Orlistat for obesity: benefits beyond weight loss. Diabetes Res Clin Pract 2005;67:78-83.
38. James WPT, Avenell A, Broom J, Whitehead J. A one-year trial to assess the value of orlistat in the management of obesity. International Journal of Obesity and Related Metabolic Disorders 1997;21(Suppl 3):S24-30.
39. Lucas CP, Boldrin MN, Reaven GM. Effect of orlistat added to diet (30% of calories from fat) on plasma lipids, glucose, and insulin in obese patients with hypercholesterolemia. Am J Cardiol 2003;91:961-4.
40. Poston WS, Reeves RS, Haddock CK, et al. Weight loss in obese Mexican Americans treated for 1-year with orlistat and lifestyle modification. Int J Obes Relat Metab Disord 2003;27:1486-93.
41. Redmon JB, Raatz SK, Kwong CA, Swanson JE, Thomas W, Bantle JE. Pharmacologic induction of weight loss to treat type 2 diabetes. Diabetes Care 1999;22:896-903.
42. Redmon JB, Raatz SK, Reck JP, et al. One-year outcome of a combination of weight loss therapies for subjects with type 2 diabetes: a randomized trial. Diabetes Care 2003;26:2505-11.
43. Redmon JB, Reck KP, Raatz SK, et al. Two-year outcome of a combination of weight loss therapies for type 2 diabetes. Diabetes Care 2005;28:1311-5.
44. Rossner S. Sibutramine - antidepressive agent tested against obesity. Ladartidningen 2001;98:1802-3.
45. Scholze J. Treating obesity with sibutramine under practical conditions. Dtsch Med Wochenschr 2002;127:606-10.
46. Toubro S, Hansen DL, Hilsted JC, Porsborg PA, Astrup AV. The effect of sibutramine for the maintenance of weight loss: a randomised, clinical, controlled study. Ugeskrift for Laeger 2001;163:2395-40.
47. Wadden TA, Berkowitz RI, Sarwer DB, Prus-Wisniewski R, Steinberg C. Benefits of lifestyle modification in the pharmacologic treatment of obesity. Archives of Internal Medicine 2001;161:218-27.
48. Wadden TA, Berkowitz RI, Womble LG, et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 2005;353:2111-20.
49. Weintraub M. Long-term weight control: The national heart, lung, and blood institute funded multimodal intervention study. Clinical Pharmacology and Therapeutics 1992;51:581-585.
50. Wirth A, Krause J. Long-term weight loss with sibutramine. Journal of the American Medical Association 2001;286:1331-9.
51. Wirth A. Reduction of body weight and co-morbidities by orlistat: the XXL - Primary Health Care Trial. Diab Obes Metab 2005;7:21-7.
52. Zavoral JH. Treatment with orlistat reduces cardiovascular risk in obese patients. J Hypertens 1998;16:2013-7.
53. ClinicalTrials.gov. Atherosclerosis underlying development assessed by intima-media thickness in patients on rimonabant (AUDITOR). http://www.clinicaltrials.gov/ct/show/NCT00228176?order=1. Accessed March 2007. December 2005.
54. ClinicalTrials.gov. CRESCENDO: comprehensive rimonabant evaluation study of cardiovascular endpoints and outcomes. http://www.clinicaltrials.gov/ct/show/NCT00263042?order=3 (accessed March 2007) December 2005.
55. James WP. The SCOUT study: risk-benefit profile of sibutramine in overweight high-risk cardiovascular patients. Eur Heart J 2005;7(suppl L):L44-8.
56. ClinicalTrials.gov. STRADIVARIUS (Strategy to reduce atherosclerosis development involving administration of rimonabant - the intravascular ultrasound study). http://www.clinicaltrials.gov/ct/show/NCT00124332?order=1. Accessed March 2007 December 2005.
57. Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996;335:609-16.
58. Allison DB, Zannolli R, Faith MS, Heo M, Pietrobelli A, VanItallie TB, et al. Weight loss increases and fat loss decreases all-cause mortality rate: results from two independent cohort studies. International Journal of Obesity and Related Metabolic Disorders 1999;23:603-11.
59. Andres R, Muller DC, Sorkin JD. Long-term effects of change in body weight on all-cause mortality. Annals of Internal Medicine 1993;119:737-43.
60. Arterburn DE, Crane PK, Veenstra DL. The efficacy and safety of sibutramine for weight loss: a systematic review. Arch Intern Med 2004;164:994-1003.
61. Birmingham CL, Muller JL, Palepu A, Spinelli JJ, Anis AH. The cost of obesity in Canada. Canadian Medical Association Journal 1999;160:483-8.
62. Blackburn G. Effect of degree of weight loss on health benefits. Obesity Research 1995;3(Supp 2):2112S-5S.
63. Bray GA. Obesity: a time bomb to be defused. Lancet 1998;352:160-1.
64. Bray GA, Tartaglia LA. Medicinal strategies in the treatment of obesity. Nature 2000;404:672-7.
65. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 2002;51:2796-803.
66. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW Jr. Body-mass index and mortality in a prospective cohort of U.S. adults. New England Journal of Medicine 1999;341:1097-105.
67. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002;359:2072-7.
68. Cohen J. A coefficient of agreement for nominal scales. Educational and Psychological Measurement 1960;20:37-46.
69. Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. Annals of Internal Medicine 1995;122:481-6.
70. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337:581-8.
71. Curioni C, Andre C. Rimonabant for overweight or obesity. Cochrane Database of Systematic Reviews 2006, Issue 4. [Art. No.:CD006162]
72. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine 2002;346:393-403.
73. The DREAM Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006;368:1096-105.
74. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. British Medical Journal 1997;315:629-34.
75. Field AE, Coakley EH, Must A, Spadano JL, Laird N, Dietz WH, et al. Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Archives of Internal Medicine 2001;161:1581-6.
76. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. Journal of the American Medical Association 2002;288:1723-27.
77. French SA, Folsom AR, Jeffery RW, Williamson DF. Prospective study of intentionality of weight loss and mortality in older women: the Iowa Women's Health Study. American Journal of Epidemiology 1999;149:504-14.
78. Goldstein DJ. Beneficial effects of modest weight loss. International Journal of Obesity and Related Metabolic Disorders 1992;16:397-415.
79. Greenway FL. Obesity surgery. Endocrinology and Metabolism Clinics of North America 1996;25:1005-27.
80. Haddock CK, Poston WSC, Dill PL, Foreyt JP, Ericsson M. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. International Journal of Obesity and Related Metabolic Disorders 2002;26:262-73.
81. Haslam DW, James WPT. Obesity. Lancet 2005;366:1197-209.
82. Health Canada. Health Canada investigates safety of MERIDIA® (Sibutramine). http://www.hc-sc.gc.ca/english/protection/warnings/2002/2002_21e.htm.
83. Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. British Medical Journal 1999;319:670-4.
84. Yusuf S, Hawken S, Ounpuu S, et al. Obesity and the risk of myocardial infarction in 27 000 participants from 52 countries: a case control study. Lancet 2005;366:1640-49.
85. International Obesity Task Force. Global obesity map. Available at http://www.iotf.org/database/documents/GlobalAdultmapswithtop5ineachregion_000.ppt. Accessed January 2007.
86. Jick H, Vasilakis C, Weinrauch LA, Meier CR, Jick SS, Derby LE. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. New England Journal of Medicine 1998;339:719-24.
87. Juni P, Smith GD, Altman DG. Assessing the quality of randomised controlled trials. In: Egger M, Smith GD, Altman DG editor(s). Systematic Reviews in Health Care. Second Edition. London: BMJ Publishing Group, 2001:87-108.
88. Kenchaiah S, Evans JC, Levy D, Wilson PWF, Benjamin, EJ, Larson MG, et al. Obesity and risk of heart failure. New England Journal of Medicine 2002;347:305-13.
89. Khan MA, Herzog CA, St Peter JV, Hartley GG, Madlon-Kay R, Dick CD, et al. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs. New England Journal of Medicine 1998;339:713-18.
90. Kissbah AH, Krakower GR. Regional adiposity and morbidity. Physiological Reviews 1994;74:761-811.
91. Kopelman PG. Obesity as a medical problem. Nature 2000;404:635-43.
92. Lau DCW. Synopsis of the 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children. CMAJ 2007;176:1103-6.
93. Lau DCW, Douketis JD, Morrison KM, et al. 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary]. CMAJ 2007;176:S1-13.
94. Lau DCW, Douketis JD, Morrison KM, et al. 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children. CMAJ 2007;176:S1-130. Available at www.cmaj.ca/cgi/content/full/176/8/S1/DC1.
95. Leibel RL, Rosenbaum M, Hirsch J. Changes in energy expenditure resulting from altered body weight. N Engl J Med 1995;332:621-8.
96. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003;326:1167-70.
97. Li Z, Maglione M, Tu W, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 2005;142:532-46.
98. The Look AHEAD Research Group. Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. Control Clin Trials 2003;24:610-28.
99. Luque CA, Rey JA. Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity. Annals of Pharmacotherapy 1999;33:968-78.
100. Manson JE, Willett WC, Stampfer MJ, Colditz GA, Hunter DJ, Hankinson SE, et al. Body weight and mortality among women. New England Journal of Medicine 1995;333:677-85.
101. McNeely W, Benfield P. Orlistat. Drugs 1998;52:241-49.
102. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup D. Improving the quality of reporting of meta-analysis of randomized controlled trials: the QUOROM statement. Lancet 1999;354:1896-900.
103. NIH Technology Assessment Conference Panel. Methods for voluntary weight loss and control. Annals of Internal Medicine 1993;119:764-70.
104. Norris SL, Zhang X, Avenell A, Gregg E, Schmid CH, Lau J. Pharmacotherapy for weight loss in adults with type 2 diabetes. Cochrane Database of Systematic Reviews 2005, Issue 1.
105. The National Task Force on Prevention and Treatment of Obesity. Towards prevention of obesity: research directions. Obes Res 1994;2:571-584.
106. O'Meara S, Riemsma R, Shirran L, Mather L, ter Riet G. A rapid and systematic review of the clinical effectiveness and cost effectiveness of orlistat in the management of obesity. Health Technology Assessment 2001; Vol. 5, issue 18. [http://www.ncchta.org/projectdata/index.asp]
107. O'Meara S, Riemsma R, Shirran L, Mather L, ter Riet G. The clinical effectiveness and cost effectiveness of sibutramine in the management of obesity: a technology assessment. Health Technology Assessment 2002; Vol. 6, issue 6. [http://www.ncchta.org/projectdata/index.asp]
108. Ogden CL, Flegal KM, Carroll MD, Johnson CL. Prevalence and trends in overweight among US children and adolescents, 1999-2000. Journal of the American Medical Association 2002;288:1728-32.
109. Padwal R, Li SK, Lau DCW. Long-term pharmacotherapy for obesity and overweight. Cochrane Database of Systematic Reviews 2003, Issue 4.
110. Padwal R, Majumdar SR, Johnson JA, Varney J, McAlister FA. A systematic review of drug therapy to delay or prevent type 2 diabetes. Diabetes Care 2005;28:736-44.
111. Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine and rimonabant. Lancet 2007;369:71-7.
112. Padwal R, Kezouh A, Levine M, Etminan M. Long-term persistence with orlistat and sibutramine in a population-based cohort. Int J Obes (Lond) 2007:In press.
113. Padwal RS. Antiobesity drug therapy: A call for more rigorous endpoint evaluation. Future Drugs 2007;4:221-6.
114. Rexrode KM, Hennekens CH, Willett WC, Colditz GA, Stampfer MJ, Rich-Edwards JW, et al. A prospective study of body mass index, weight change, and risk of stroke in women. Journal of the American Medical Association 1997;277:1539-45.
115. Rimm EB, Stampfer MJ, Giovannucci E, Ascherio A, Spiegelman D, Colditz GA, Willett WC. Rimm EB, Stampfer MJ, Giovannucci E, Ascherio A, Spiegelman D, Colditz GA, et al. Body size and fat distribution as predictors of coronary heart disease among middle-aged and older US men. American Journal of Epidemiology 1995;141:1117-27.
116. Seidell JC. The impact of obesity on health status: some implications for health care costs. International Journal of Obesity and Related Metabolic Disorders 1996;19(Suppl 6):S13-S16.
117. Sjostrom L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004;351:2683-93.
118. Sterne JAC, Egger M, Smith GD. Investigating and dealing with publication and other biases. In: Egger M, Smith GD, Altman DG editor(s). Systematic Reviews in Health Care. Second Edition. London: BMJ Publishing Group, 2001.
119. Stevens J, Cai J, Pamuk ER, Williamson DF, Thun MJ, Wood JL. The effect of age on the association between body-mass index and mortality. New England Journal of Medicine 1998;338:1-7.
120. Toumilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine 2001;344:1343-50.
121. Expert Panel on the Identification, Evaluation and Treatment of Overweight and Obesity in Adults. Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Archives of Internal Medicine 1998;158:1855-67.
122. Bray GA. Health hazards associated with obesity. UpToDate Clinical Reference Library [CD-ROM] 2001; Vol. Version 9.1.
123. Verhagen AP, de Vet HC, de Bie RA, Kessels AG, Boers M, Bouter LM, et al. The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. Journal of Clinical Epidemiology 1998;51:1235-31.
124. Visscher TL, Seidell JC, Molarius A, van der Kuip D, Hofman A, Witteman JC. A comparison of body mass index, waist-hip ratio and waist circumference as predictors of all-cause mortality among the elderly: the Rotterdam study. International Journal of Obesity and Related Metabolic Disorders 2001;25:1730-5.
125. Wadden TA. Treatment of obesity by moderate and severe caloric restriction. Results of clinical research trials. Annals of Internal Medicine 1993;119:688-93.
126. Weissman NJ, Tighe JF Jr, Gottdiener JS, Gwynne JT. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. New England Journal of Medicine 1998;339:725-32.
127. World Health Organisation (WHO). Obesity: Preventing and managing the Global Epidemic - Report of a WHO Consultation on Obesity, 3-5 June 1997. WHO/NUT/NCD/98.1 1998.
128. Williamson DF, Pamuk ER. The association between weight loss and increased longevity. A review of the evidence. Annals of Internal Medicine 1993;119:731-36.
129. Williamson DF, Pamuk E, Thun M, Flanders D, Byers T, Heath C. Prospective study of intentional weight loss and mortality in never-smoking overweight US white women aged 40-64 years. American Journal of Epidemiology 1995;141:1128-41.
130. Wing RR, Marcus MD, Epstein LH, Salata R. Type 2 diabetic subjects lose less weight than their overweight spouses. Diabetes Care 2000;23:1499-1504.
131. Wooltorton 2002. Obesity drug sibutramine (Meridia): hypertension and cardiac arrhythmias. Canadian Medical Association Journal 2002;166:1307-8.